



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	27H8.00
True Name	Mycoplasma Hyorhinis Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Ingelvac MycoMax - No distributor specified
Date of Compilation Summary	October 28, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy																								
Pertaining to	Mycoplasma Hyorhinis Bacterin																								
Study Purpose	Demonstration of efficacy																								
Product Administration	Single intramuscular administration of vaccine																								
Study Animals	56 pigs, 3 weeks of age, divided into 28 vaccinates and 28 controls. 27 vaccinates and 27 controls were challenged																								
Challenge Description	Challenged with virulent <i>M. hyorhinis</i> , consecutively for 3 days on days 22, 23 and 24 after vaccination																								
Interval observed after challenge	Pigs were observed daily for 3 weeks after challenge																								
Results	<p>Summary of Results Following Challenge:</p> <table border="1"> <thead> <tr> <th>Observation</th> <th>Vaccinates (N=27)</th> <th>Controls (n=27)</th> </tr> </thead> <tbody> <tr> <td>Pre-mortem Lameness¹</td> <td>4</td> <td>15</td> </tr> <tr> <td>Pre-mortem Respiratory Signs²</td> <td>3</td> <td>5</td> </tr> <tr> <td>Pericarditis³</td> <td>11</td> <td>26</td> </tr> <tr> <td>Pleuritis³</td> <td>8</td> <td>11</td> </tr> <tr> <td>Arthritis</td> <td>5</td> <td>26</td> </tr> <tr> <td>Peritonitis</td> <td>6</td> <td>14</td> </tr> <tr> <td>Affected⁴</td> <td>14</td> <td>27</td> </tr> </tbody> </table> <p>¹Lameness was defined as visible lameness for 2 or more consecutive days. ²Respiratory signs were any observations of abnormal respiration or cough. ³Pleuritis and/or Pericarditis were coded as “Respiratory Distress”. ⁴A pig was considered affected following challenge if lameness was observed for 2 or more consecutive days or if respiratory distress (pleuritis or pericarditis), arthritis, or peritonitis was observed at necropsy.</p> <p>Raw Data: shown on the following pages.</p>	Observation	Vaccinates (N=27)	Controls (n=27)	Pre-mortem Lameness ¹	4	15	Pre-mortem Respiratory Signs ²	3	5	Pericarditis ³	11	26	Pleuritis ³	8	11	Arthritis	5	26	Peritonitis	6	14	Affected⁴	14	27
Observation	Vaccinates (N=27)	Controls (n=27)																							
Pre-mortem Lameness ¹	4	15																							
Pre-mortem Respiratory Signs ²	3	5																							
Pericarditis ³	11	26																							
Pleuritis ³	8	11																							
Arthritis	5	26																							
Peritonitis	6	14																							
Affected⁴	14	27																							
USDA Approval Date	February 10, 2016																								

Controls:

Pig #	Total Days Lame	>=2 consecutive days with lameness	Pericarditis Score 1=mild 2=moderate 3=severe	Pleuritis	Arthritis 1=positive	Peritonitis
8	18	yes	2	No	1	No
9	0	No	2	Yes	1	Yes
24	2	Yes	2	No	1	Yes
29	5	Yes	2	No	1	No
31	0	No	3	Yes	1	Yes
35	2	Yes	2	Yes	1	Yes
38	11	Yes	2	Yes	1	Yes
39	6	Yes	2	No	1	Yes
44	0	No	2	No	1	No
47	1	No	3	Yes	1	Yes
49	12	Yes	2	No	1	Yes
52	5	Yes	3	Yes	1	No
53	9	Yes	2	No	1	Yes
56	8	Yes	2	No	1	No
65	0	No	2	No	1	No
74	3	Yes	0	No	1	Yes
75	0	No	2	No	1	No
86	4	Yes	2	No	1	No
88	14	Yes	3	No	1	Yes
89	11	Yes	2	Yes	1	Yes
93	2	No	2	Yes	1	No
95	0	No	2	No	1	No
98	0	No	3	No	1	No
101	1	No	3	No	1	No
116	0	No	3	Yes	0	No
117	0	No	2	Yes	1	Yes
118	14	Yes	2	Yes	1	Yes

Vaccinates:

Pig #	Total Days Lame	>=2 consecutive days with lameness	Pericarditis Score 1=mild 2=moderate 3=severe	Pleuritis	Arthritis 1=positive	Peritonitis
2	0	No	2	No	0	No
7	0	No	0	No	0	No
12	2	No	2	No	1	Yes
18	7	Yes	2	Yes	0	No
20	0	No	0	No	0	No
21	0	No	0	No	0	No
22	0	No	0	No	0	No
27	0	No	0	No	0	No
34	0	No	0	No	0	No
40	0	No	0	No	0	No
42	0	No	3	Yes	0	Yes
57	0	No	0	Yes	0	No
58	0	No	2	Yes	1	Yes
60	0	No	2	Yes	1	No
61	0	No	3	No	0	No
69	1	No	0	No	1	Yes
77	0	No	0	No	0	No
79	0	No	0	No	0	No
81	0	No	0	No	0	No
85	4	Yes	3	Yes	0	Yes
90	0	No	3	Yes	0	Yes
102	1	No	2	No	0	No
104	3	Yes	2	Yes	1	No
106	5	Yes	0	No	0	No
112	0	No	0	No	0	No
114	0	No	0	No	0	No
120	0	No	0	No	0	No

Study Type	Efficacy																		
Pertaining to	Mycoplasma Hyorhinis Bacterin																		
Study Purpose	Demonstration of duration of immunity																		
Product Administration	Single intramuscular administration of vaccine																		
Study Animals	64 pigs, 3 weeks of age, divided into 32 vaccinates and 32 controls (31 controls were challenged)																		
Challenge Description	Challenged with virulent <i>M. hyorhinis</i> , consecutively for 3 days 7 weeks after vaccination																		
Interval observed after challenge	Pigs were observed daily for 3 weeks after challenge																		
Results	<p>Summary of Results Following Challenge:</p> <table border="1"> <thead> <tr> <th>Observation</th> <th>Vaccinates (N=32)</th> <th>Controls (n=31)</th> </tr> </thead> <tbody> <tr> <td>Pre-mortem Lameness¹</td> <td>6</td> <td>19</td> </tr> <tr> <td>Pre-mortem Respiratory Signs²</td> <td>2</td> <td>4</td> </tr> <tr> <td>Pericarditis³</td> <td>1</td> <td>8</td> </tr> <tr> <td>Arthritis</td> <td>3</td> <td>19</td> </tr> <tr> <td>Affected⁴</td> <td>11</td> <td>26</td> </tr> </tbody> </table> <p>¹Lameness was defined as visible lameness for 2 or more consecutive days. ²Respiratory signs were any observations of abnormal respiration or cough. ³ Pericarditis was coded as an indicator of Respiratory Disease and coded as “Respiratory Distress”. ⁴ An animal was considered affected following challenge if, lameness was observed for 2 or more consecutive days, or respiratory distress, or pericarditis or arthritis were observed at necropsy.</p> <p>Raw Data: shown on the following pages.</p>	Observation	Vaccinates (N=32)	Controls (n=31)	Pre-mortem Lameness ¹	6	19	Pre-mortem Respiratory Signs ²	2	4	Pericarditis ³	1	8	Arthritis	3	19	Affected⁴	11	26
Observation	Vaccinates (N=32)	Controls (n=31)																	
Pre-mortem Lameness ¹	6	19																	
Pre-mortem Respiratory Signs ²	2	4																	
Pericarditis ³	1	8																	
Arthritis	3	19																	
Affected⁴	11	26																	
USDA Approval Date	October 14, 2016																		

Controls:

Pig ID	Respiratory signs (days duration)	Total Days Lame	Lameness >=2 consecutive days 1=yes, 0=no	Pericarditis Score 1=mild 2=moderate 3=severe	Arthritis 1=positive
21	0	0	0	2	0
24	0	0	0	0	1
33	0	0	0	0	0
36	0	0	0	0	0
37	0	4	1	0	1
41	0	7	1	0	1
44	AR (3)	15	1	0	1
45	AR (1)	15	1	2	1
49	0	13	1	0	1
56	0	13	1	0	0
64	0	5	1	0	1
66	0	6	1	0	1
68	0	7	1	0	1
70	0	0	0	2	1
72	0	14	1	0	1
75	0	0	0	0	0
77	0	22*	1	0	0
88	0	1	0	0	0
89	0	14	1	0	0
95	0	0	0	0	1
98	0	0	0	2	0
101	0	10	1	0	1
103	AR (1)	20	1	2	1
107	0	0	0	0	0
108	AR (1)	15	1	2	1
114	0	11	1	0	0
115	0	0	0	3	1
119	0	8	1	2	1
122	0	0	0	0	1
136	0	8	1	0	0
139	0	12	1	0	1

*lameness also observed prior to challenge

AR=Abnormal Respiration

Vaccinates:

Pig ID	Respiratory signs (days duration)	Total Days Lame	Lameness >=2 consecutive days 1=yes, 0=no	Pericarditis Score 1=mild 2=moderate 3=severe	Arthritis 1=positive
3	0	14	1	0	1
19	0	0	0	0	0
30	0	0	0	0	0
32	0	0	0	0	0
39	0	0	0	0	0
47	0	4	1	0	0
51	0	0	0	0	0
53	0	2	1	0	0
57	0	0	0	0	0
58	C (1)	0	0	0	0
61	0	13	1	0	0
71	0	0	0	0	0
79	0	0	0	0	0
82	0	0	0	0	0
84	0	0	0	0	0
86	0	5	1	0	0
92	C (2)	0	0	0	0
93	0	0	0	0	0
94	0	0	0	0	0
99	0	0	0	0	0
100	0	0	0	0	1
104	0	0	0	0	1
109	0	0	0	0	0
111	0	0	0	0	0
116	0	0	0	0	0
120	0	0	0	0	0
124	0	0	0	1	0
125	0	0	0	0	0
130	0	0	0	0	0
131	0	7	1	0	0
133	0	0	0	0	0
135	0	0	0	0	0

C=Cough

Study Type	Safety																																																																																																																																								
Pertaining to	Mycoplasma Hyorhinis Bacterin																																																																																																																																								
Study Purpose	To demonstrate safety under field conditions																																																																																																																																								
Product Administration	Single intramuscular administration of vaccine																																																																																																																																								
Study Animals	767 weaned pigs approximately 3 weeks of age																																																																																																																																								
Challenge Description	Not applicable																																																																																																																																								
Interval observed after challenge	Pigs were observed daily for 14 days following vaccination																																																																																																																																								
Results	<p>Number of pigs by site with any listed clinical observations, occurring at least once during the 14 day study duration:</p> <p>A total of 109 adverse events were observed. Four animals showed both injection site reactions and systemic reactions.</p> <table border="1"> <thead> <tr> <th>Clinical Observation</th> <th>IL Site N=242</th> <th>MO Site N=250</th> <th>NC Site 1 N=81</th> <th>NC Site 2¹ N=194</th> <th>Total Animals N=767</th> </tr> </thead> <tbody> <tr> <td>Normal²</td> <td>206</td> <td>239</td> <td>60</td> <td>157</td> <td>662</td> </tr> <tr> <td>Loss of condition</td> <td>24</td> <td>2</td> <td>6</td> <td>14</td> <td>46</td> </tr> <tr> <td>Injection site rxn³</td> <td>6</td> <td>0</td> <td>7</td> <td>6</td> <td>19</td> </tr> <tr> <td>Mortality⁴</td> <td>3</td> <td>4</td> <td>2</td> <td>6</td> <td>15</td> </tr> <tr> <td>Diarrhea</td> <td>3</td> <td>0</td> <td>0</td> <td>11</td> <td>14</td> </tr> <tr> <td>Dyspnea</td> <td>1</td> <td>5</td> <td>3</td> <td>2</td> <td>11</td> </tr> <tr> <td>Cough</td> <td>3</td> <td>0</td> <td>1</td> <td>5</td> <td>9</td> </tr> <tr> <td>Lameness</td> <td>1</td> <td>4</td> <td>2</td> <td>2</td> <td>9</td> </tr> <tr> <td>Anaphylaxis⁵</td> <td>0</td> <td>1</td> <td>6</td> <td>1</td> <td>8</td> </tr> <tr> <td>Lethargy</td> <td>5</td> <td>0</td> <td>1</td> <td>1</td> <td>7</td> </tr> <tr> <td>Emesis⁵</td> <td>0</td> <td>0</td> <td>0</td> <td>6</td> <td>6</td> </tr> <tr> <td>Recumbency⁵</td> <td>1</td> <td>0</td> <td>0</td> <td>4</td> <td>5</td> </tr> <tr> <td>Ataxia⁴</td> <td>1</td> <td>0</td> <td>0</td> <td>3</td> <td>4</td> </tr> <tr> <td>Aural hematoma</td> <td>0</td> <td>0</td> <td>2</td> <td>0</td> <td>2</td> </tr> <tr> <td>Poor Coat Condition</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>2</td> </tr> <tr> <td>Nystagmus</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> <tr> <td>Paddling</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> <tr> <td>Pallor</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> <tr> <td>Pinnal reddening</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td> </tr> <tr> <td>Sneezing</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> </tr> <tr> <td>Tachypnea</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> </tbody> </table> <p>¹Site 2 in North Carolina is an antibiotic free herd, treatment is limited. ²For “normal” a pig had to be observed to be without adverse events for the entire 14 days of the study. ³rxn= reaction. All injections site swellings observed were <1 inch in</p>					Clinical Observation	IL Site N=242	MO Site N=250	NC Site 1 N=81	NC Site 2 ¹ N=194	Total Animals N=767	Normal²	206	239	60	157	662	Loss of condition	24	2	6	14	46	Injection site rxn ³	6	0	7	6	19	Mortality ⁴	3	4	2	6	15	Diarrhea	3	0	0	11	14	Dyspnea	1	5	3	2	11	Cough	3	0	1	5	9	Lameness	1	4	2	2	9	Anaphylaxis ⁵	0	1	6	1	8	Lethargy	5	0	1	1	7	Emesis ⁵	0	0	0	6	6	Recumbency ⁵	1	0	0	4	5	Ataxia ⁴	1	0	0	3	4	Aural hematoma	0	0	2	0	2	Poor Coat Condition	1	0	1	0	2	Nystagmus	1	0	0	0	1	Paddling	1	0	0	0	1	Pallor	1	0	0	0	1	Pinnal reddening	0	0	0	1	1	Sneezing	0	0	1	0	1	Tachypnea	1	0	0	0	1
Clinical Observation	IL Site N=242	MO Site N=250	NC Site 1 N=81	NC Site 2 ¹ N=194	Total Animals N=767																																																																																																																																				
Normal²	206	239	60	157	662																																																																																																																																				
Loss of condition	24	2	6	14	46																																																																																																																																				
Injection site rxn ³	6	0	7	6	19																																																																																																																																				
Mortality ⁴	3	4	2	6	15																																																																																																																																				
Diarrhea	3	0	0	11	14																																																																																																																																				
Dyspnea	1	5	3	2	11																																																																																																																																				
Cough	3	0	1	5	9																																																																																																																																				
Lameness	1	4	2	2	9																																																																																																																																				
Anaphylaxis ⁵	0	1	6	1	8																																																																																																																																				
Lethargy	5	0	1	1	7																																																																																																																																				
Emesis ⁵	0	0	0	6	6																																																																																																																																				
Recumbency ⁵	1	0	0	4	5																																																																																																																																				
Ataxia ⁴	1	0	0	3	4																																																																																																																																				
Aural hematoma	0	0	2	0	2																																																																																																																																				
Poor Coat Condition	1	0	1	0	2																																																																																																																																				
Nystagmus	1	0	0	0	1																																																																																																																																				
Paddling	1	0	0	0	1																																																																																																																																				
Pallor	1	0	0	0	1																																																																																																																																				
Pinnal reddening	0	0	0	1	1																																																																																																																																				
Sneezing	0	0	1	0	1																																																																																																																																				
Tachypnea	1	0	0	0	1																																																																																																																																				

	<p>size. Swellings resolved within 1-3 days.</p> <p>⁴One death was attributed to anaphylactic reaction post vaccination. Two deaths attributed to <i>M. hyorhinis</i> systemic infection. Other deaths affirmed by investigator to have cause other than vaccination or <i>M. hyorhinis</i> infection.</p> <p>⁵These observations generally occurred immediately following vaccination. The majority recovered within 15 minutes, without intervention.</p>
USDA Approval Date	October 5, 2017